ERA

Download the full-sized PDF of Understanding the Mode of Action of Trastuzumab to Design a Better Therapy for ErbB2-positive Human Breast CancerDownload the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R36688X26

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

Understanding the Mode of Action of Trastuzumab to Design a Better Therapy for ErbB2-positive Human Breast Cancer Open Access

Descriptions

Other title
Subject/Keyword
ErbB2-breast cancer
Trastuzumab
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Elian, Fahed Ah
Supervisor and department
Walter, Michael (Medical Genetics)
Wang, Zhixiang (Medical Genetics)
Examining committee member and department
Postovit, Lynne-Marie (Oncology)
Eisenstat, David (Medical Genetics)
Hitt, Mary (Oncology)
Department
Medical Sciences-Medical Genetics
Specialization

Date accepted
2016-01-19T14:14:18Z
Graduation date
2016-06
Degree
Master of Science
Degree level
Master's
Abstract
Overexpression of ErbB2 occurs in about 25-30% of breast cancer cases and therefore, represents an attractive therapeutic target for treating breast cancer. There are two models for ErbB2 inhibitors that are currently in clinical use: humanized antibodies directed against ErbB2 and small molecule tyrosine-kinase inhibitors. Patients with ErbB2-positive breast cancer have significantly lower survival rates and a shorter period before relapse than patients without ErbB2 overexpression. Trastuzumab (Herceptin) is a humanized recombinant mAb that binds to the extracellular domain of ErbB2 protein. Although, the exact antitumor mechanisms for trastuzumab are not precisely known, several possibilities have been proposed. Here, we show that trastuzumab is able to block pErbB2 and pEGFR in a ligand-dependent manner. Trastuzumab was able to inhibit both pEGFR and pErbB2 in CHO cell lines that express each receptor alone. Moreover, we show that trastuzumab is able to inhibit the phosphorylation of AKT and Erk that are activated by EGFR and ErbB2 in a ligand-independent manner. Pharmacologically, we found trastuzumab was neither able to significantly inhibit cell proliferation and survival nor enhance the cytotoxic effect of doxorubicin.
Language
English
DOI
doi:10.7939/R36688X26
Rights
This thesis is made available by the University of Alberta Libraries with permission of the copyright owner solely for the purpose of private, scholarly or scientific research. This thesis, or any portion thereof, may not otherwise be copied or reproduced without the written consent of the copyright owner, except to the extent permitted by Canadian copyright law.
Citation for previous publication

File Details

Date Uploaded
Date Modified
2016-01-19T22:26:32.290+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (PDF/A)
Mime type: application/pdf
File size: 4448168
Last modified: 2016:10:29 01:35:19-06:00
Filename: Elian_Fahed_A_201601_MSc.pdf.pdf
Original checksum: 2c7a959d536e4b5df41e1e97c80cc455
Activity of users you follow
User Activity Date